Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

Voriconazole in the management of nosocomial invasive fungal infections

Authors Javier Pemán, Miguel Salavert, Emilia Cantón, Isidro Jarque, Eva Romá, et al

Published 15 June 2006 Volume 2006:2(2) Pages 129—158

Javier Pemán1, Miguel Salavert2, Emilia Cantón3, Isidro Jarque4, Eva Romá5, Rafael Zaragoza6, Ángel Viudes7, Miguel Gobernado1

 

1Microbiology Department, Hospital Universitario La Fe, Valencia, Spain; 2Infectious Diseases Unit, Hospital Universitario La Fe, Valencia, Spain; 3Experimental Microbiology Unit, Hospital Universitario La Fe, Valencia, Spain; 4Hematology Department, Hospital Universitario La Fe, Valencia, Spain; 5Pharmacy Department, Hospital Universitario La Fe, Valencia, Spain; 6Intensive Care Unit, Hospital Universitario Dr. Peset, Valencia, Spain; 7Medical Department, Pfizer, Madrid, Spain

 

Abstract: Voriconazole is a new triazole developed for the treatment of life-threatening fungal infections. The drug is available for both oral and intravenous administration; the oral formulation has excellent bioavailability. The side-effect profile of voriconazole presents an acceptable safety and tolerability spectrum: transient visual disturbances, liver enzyme abnormalities, and skin rashes are the most frequently reported side effects but rarely lead to discontinuation. The potential for drug–drug interactions is high, because of its extensive hepatic metabolism. Careful attention to dosage is required, and serum levels and the effects of interacting drugs should be monitored. Review of 25 470 isolates of yeasts and 3216 isolates of filamentous fungi showed voriconazole to have broad-spectrum activity against pathogenic yeasts including intrinsically fluconazole-resistant isolates such as Candida krusei, dimorphic fungi, and opportunistic moulds like Aspergillus spp, amphotericin-B-resistant Aspergillus terreus, Fusarium spp, and Scedosporium apiospermum. It displays excellent clinical efficacy in patients with fluconazole-resistant and -susceptible Candida infections, invasive bone and central nervous system aspergillosis, and various refractory fungal infections. Voriconazole has been approved by the US Food and Drug Administration and by the European Medicines Agency for the treatment of invasive aspergillosis, serious infections caused by Fusarium and S. apiospermum, fluconazole-resistant invasive Candida infections, and candidemia in nonneutropenic patients.

 

 

Keywords: voriconazole, azole, mycoses, treatment, yeasts, moulds

Download Article [PDF] 

Readers of this article also read:

Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine

Zhao K, Rong G, Guo C, Luo X, Kang H, Sun Y, Dai C, Wang X, Wang X, Jin Z, Cui S, Sun Q

International Journal of Nanomedicine 2015, 10:2895-2911

Published Date: 13 April 2015

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer

Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ

Cancer Management and Research 2014, 6:437-449

Published Date: 23 October 2014

Titanate nanowire scaffolds decorated with anatase nanocrystals show good protein adsorption and low cell adhesion capacity

Ding XL, Yang XQ, Zhou L, Lu HB, Li SB, Gao Y, Lai CH, Jiang Y

International Journal of Nanomedicine 2013, 8:569-579

Published Date: 7 February 2013

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

Peter Bramlage

Vascular Health and Risk Management 2009, 5:213-224

Published Date: 11 February 2009

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Therapeutics and Clinical Risk Management 2008, 4:821-826

Published Date: 8 August 2008

New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor

Fabrizio Montecucco, François Mach

Clinical Interventions in Aging 2008, 3:341-349

Published Date: 6 June 2008

Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease

Gjumrakch Aliev, Eldar Gasimov, Mark E Obrenovich, Kathryn Fischbach, Justin C Shenk, et al

Vascular Health and Risk Management 2008, 4:721-730

Published Date: 6 June 2008

Adherence to disease management programs in patients with COPD

Johnson George, David CM Kong, Kay Stewart

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:253-262

Published Date: 15 October 2007